What are the presentation, diagnostic criteria, and recommended treatment for polymyalgia rheumatica in adults over 50?

Polymyalgia Rheumatica: Clinical Overview

Polymyalgia rheumatica (PMR) is an inflammatory disease affecting adults over 50 years, requiring prompt treatment with glucocorticoids at 12.5-25 mg prednisone daily, with IL-6 receptor inhibitors (tocilizumab or sarilumab) now established as effective glucocorticoid-sparing agents for patients at high risk of steroid complications or relapse. 1, 2, 3

Clinical Presentation

PMR presents with:

• Bilateral shoulder and hip girdle pain and stiffness that is worse in the morning and improves with activity
• Neck pain commonly accompanies proximal symptoms
• Constitutional symptoms including fatigue, low-grade fever, weight loss
• Age >50 years (typically >60 years; younger age suggests alternative diagnosis)
• Elevated inflammatory markers: ESR and/or CRP are elevated in most cases, though normal markers don't exclude PMR 1

Key atypical features requiring specialist referral:

• Peripheral inflammatory arthritis
• Age <60 years
• Low or normal inflammatory markers
• Prominent systemic symptoms
• Poor response to glucocorticoids 1

Diagnostic Approach

Essential Pre-Treatment Workup

Before initiating therapy, obtain 1:

Laboratory tests:

• ESR and/or CRP
• Complete blood count
• Rheumatoid factor and/or anti-CCP antibodies (to exclude rheumatoid arthritis)
• Glucose, creatinine, liver function tests
• Bone profile (calcium, alkaline phosphatase)
• Urinalysis
• Consider: protein electrophoresis, TSH, creatine kinase, vitamin D

Additional testing based on clinical suspicion:

• ANA, ANCA (if vasculitis suspected)
• Tuberculosis screening
• Chest radiograph (to exclude malignancy, infection)

Critical exclusion: Rule out giant cell arteritis (GCA), which coexists in 16-21% of PMR cases. Screen for jaw claudication, new headache, visual symptoms, scalp tenderness, and temporal artery abnormalities 4, 5.

Comorbidity Assessment

Document baseline comorbidities that increase glucocorticoid toxicity risk 1:

• Hypertension, diabetes, glucose intolerance
• Cardiovascular disease, dyslipidemia
• Osteoporosis (especially recent fractures)
• Cataracts or glaucoma risk factors
• Peptic ulcer disease
• Chronic/recurrent infections
• Current NSAID use

Risk factors for relapse/prolonged therapy (though evidence is mixed): female sex, ESR >40 mm/hr, peripheral inflammatory arthritis 1

Treatment Algorithm

Initial Glucocorticoid Therapy

Start prednisone 12.5-25 mg daily (oral, single morning dose) 1:

Dose selection within this range:

• Higher dose (20-25 mg): Patients with high relapse risk and low adverse event risk
• Lower dose (12.5-15 mg): Patients with diabetes, osteoporosis, glaucoma, hypertension, or other glucocorticoid toxicity risk factors

Strongly avoid:

• Initial doses ≤7.5 mg/day (inadequate)
• Initial doses >30 mg/day (excessive toxicity risk) 1

Alternative: Intramuscular methylprednisolone 120 mg every 3 weeks may be considered in patients requiring lower cumulative glucocorticoid exposure (e.g., women with difficult-to-control hypertension, diabetes, osteoporosis, or glaucoma), though evidence for reduced side effects is limited 1

Expected Response and Diagnosis Confirmation

• Clinical improvement should occur within 2-4 weeks 1
• Dramatic response to glucocorticoids supports PMR diagnosis
• If no improvement: Reassess diagnosis; consider alternative conditions or GCA

Glucocorticoid Tapering Schedule

Initial taper (weeks 0-8): Reduce to 10 mg/day prednisone over 4-8 weeks 1

Maintenance taper: Once remission achieved, reduce by 1 mg every 4 weeks (or 1.25 mg decrements using alternate-day schedules like 10/7.5 mg) until discontinuation, provided remission is maintained 1

Relapse management: Increase to pre-relapse dose, then taper gradually over 4-8 weeks back to the dose where relapse occurred 1

Glucocorticoid-Sparing Agents

IL-6 receptor inhibitors are now first-line adjunctive therapy for selected patients 2, 3:

Consider early introduction of tocilizumab or sarilumab in patients with:

• High risk for glucocorticoid-related adverse events (diabetes, osteoporosis, glaucoma)
• High risk for relapse or prolonged therapy
• Glucocorticoid resistance or intolerance
• Relapsing disease 1

Recent high-quality trials demonstrate IL-6R inhibitors consistently achieve higher remission rates and reduce cumulative glucocorticoid exposure 3. Sarilumab received FDA approval for refractory PMR 6.

Methotrexate 7.5-10 mg/week may be considered as an alternative glucocorticoid-sparing agent, though efficacy is more limited than IL-6R inhibitors 1, 3

Strongly avoid:

• TNF-α blocking agents (ineffective) 1
• Chinese herbal preparations (Yanghe, Biqi capsules) 1

Monitoring Protocol

Follow-up schedule 1:

• First year: Every 4-8 weeks
• Second year: Every 8-12 weeks
• During taper or relapse: As clinically indicated

At each visit, assess:

• Disease activity (pain, stiffness, functional status)
• Inflammatory markers (ESR, CRP)
• Glucocorticoid-related adverse events
• Comorbidity status
• Medication adherence

Ensure rapid access to medical advice for patients to report flares or adverse events 1

Common Pitfalls and Caveats

1. Missing concurrent GCA: Always screen for GCA symptoms; delayed diagnosis risks permanent vision loss or stroke 4, 7

2. Inadequate initial dosing: Doses <12.5 mg often fail to control disease, leading to prolonged symptoms and delayed diagnosis confirmation 1

3. Excessive initial dosing: Doses >30 mg increase toxicity without additional benefit 1

4. Too-rapid tapering: Increases relapse risk; individualize based on clinical response and inflammatory markers 1

5. Glucocorticoid toxicity in elderly: This population is particularly vulnerable to hyperglycemia, osteoporosis, infections, and cardiovascular complications—proactive monitoring and bone protection are essential 1, 7

6. Overlooking glucocorticoid-sparing options: With IL-6R inhibitors now proven effective, consider early introduction in high-risk patients rather than waiting for complications 2, 3

7. Using NSAIDs as primary therapy: NSAIDs are ineffective for PMR and should only be used short-term for pain from other conditions 1

Specialist Referral Indications

Refer to rheumatology for 1:

• Atypical presentation (age <60, peripheral arthritis, low inflammatory markers)
• Suspected or confirmed GCA
• Glucocorticoid-refractory disease
• Frequent relapses or prolonged therapy requirement
• High risk or established glucocorticoid-related adverse events

Adjunctive Management

• Individualized exercise program: Maintain muscle mass, reduce fall risk in elderly patients on long-term glucocorticoids 1
• Patient education: Disease course, treatment expectations, glucocorticoid side effects, self-monitoring for flares 1
• Osteoporosis prevention: Calcium, vitamin D, bisphosphonates as indicated
• Cardiovascular risk management: Address hypertension, diabetes, dyslipidemia